Zinc finger proteins and ATP-binding cassette transporter-dependent multidrug resistance.
ABC transporters
cancer
chemoresistance
multidrug resistance
tumor microenvironment
zinc finger proteins
Journal
European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331
Informations de publication
Date de publication:
06 Nov 2023
06 Nov 2023
Historique:
revised:
12
07
2023
received:
12
01
2023
accepted:
02
10
2023
medline:
6
11
2023
pubmed:
6
11
2023
entrez:
6
11
2023
Statut:
aheadofprint
Résumé
Multidrug resistance (MDR) remains a significant challenge in cancer treatment, leading to poor clinical outcomes. Dysregulation of ATP-binding cassette (ABC) transporters has been identified as a key contributor to MDR. Zinc finger proteins (ZNPs) are key regulators of transcription and have emerged as potential contributors to cancer drug resistance. Bridging the knowledge gap between ZNPs and MDR is essential to understand a source of heterogeneity in cancer treatment. This review sought to elucidate how different ZNPs modulate the transcriptional regulation of ABC genes, contributing to resistance to cancer therapies. The search was conducted using PubMed, Google Scholar, EMBASE and Web of Science. In addition to ABC-blockers, the transcriptional features regulated by ZNP are expected to play a role in reversing ABC-mediated MDR and predicting the efficacy of anticancer treatments. Among the ZNP-induced epithelial to mesenchymal transition, SNAIL, SLUG and Zebs have been identified as important factors in promoting MDR through activation of ATM, NFκB and PI3K/Akt pathways, exposing the metabolism to potential ZNP-MDR interactions. Additionally, nuclear receptors, such as VDR, ER and PXR have been found to modulate certain ABC regulations. Other C2H2-type zinc fingers, including Kruppel-like factors, Gli and Sp also have the potential to contribute to MDR. Besides reviewing evidence on the effects of ZNP dysregulation on ABC-related chemoresistance in malignancies, significant markers of ZNP functions are discussed to highlight the clinical implications of gene-to-gene and microenvironment-to-gene interactions on MDR prospects. Future research on ZNP-derived biomarkers is crucial for addressing heterogeneity in cancer therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Multidrug resistance (MDR) remains a significant challenge in cancer treatment, leading to poor clinical outcomes. Dysregulation of ATP-binding cassette (ABC) transporters has been identified as a key contributor to MDR. Zinc finger proteins (ZNPs) are key regulators of transcription and have emerged as potential contributors to cancer drug resistance. Bridging the knowledge gap between ZNPs and MDR is essential to understand a source of heterogeneity in cancer treatment. This review sought to elucidate how different ZNPs modulate the transcriptional regulation of ABC genes, contributing to resistance to cancer therapies.
METHODS
METHODS
The search was conducted using PubMed, Google Scholar, EMBASE and Web of Science.
RESULTS
RESULTS
In addition to ABC-blockers, the transcriptional features regulated by ZNP are expected to play a role in reversing ABC-mediated MDR and predicting the efficacy of anticancer treatments. Among the ZNP-induced epithelial to mesenchymal transition, SNAIL, SLUG and Zebs have been identified as important factors in promoting MDR through activation of ATM, NFκB and PI3K/Akt pathways, exposing the metabolism to potential ZNP-MDR interactions. Additionally, nuclear receptors, such as VDR, ER and PXR have been found to modulate certain ABC regulations. Other C2H2-type zinc fingers, including Kruppel-like factors, Gli and Sp also have the potential to contribute to MDR.
CONCLUSION
CONCLUSIONS
Besides reviewing evidence on the effects of ZNP dysregulation on ABC-related chemoresistance in malignancies, significant markers of ZNP functions are discussed to highlight the clinical implications of gene-to-gene and microenvironment-to-gene interactions on MDR prospects. Future research on ZNP-derived biomarkers is crucial for addressing heterogeneity in cancer therapy.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14120Informations de copyright
© 2023 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.
Références
Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer. 2018;18(7):452-464.
Garattini S. Pharmacokinetics in cancer chemotherapy. Eur J Cancer. 2007;43(2):271-282.
Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5(3):219-234.
Muriithi W, Macharia LW, Heming CP, et al. ABC transporters and the hallmarks of cancer: roles in cancer aggressiveness beyond multidrug resistance. Cancer Biol Med. 2020;17(2):253.
Scotto KW. Transcriptional regulation of ABC drug transporters. Oncogene. 2003;22(47):7496-7511.
Xiao H, Zheng Y, Ma L, Tian L, Sun Q. Clinically-relevant ABC transporter for anti-cancer drug resistance. Front Pharmacol. 2021;12:648407.
Hano M, Tomášová L, Šereš M, Pavlíková L, Breier A, Sulová Z. Interplay between P-glycoprotein expression and resistance to endoplasmic reticulum stressors. Molecules. 2018;23(2):337.
Hooijberg JH, Broxterman HJ, Kool M, et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 1999;59:2532-2535.
Allen JD, Brinkhuis RF, van Deemter L, Wijnholds J, Schinkel AH. Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. Cancer Res. 2000;60(20):5761-5766.
Grzywacz MJ, Yang J-M, Hait WN. Effect of the multidrug resistance protein on the transport of the antiandrogen flutamide. Cancer Res. 2003;63(10):2492-2498.
He S-M, Li R, Kanwar JR, Zhou S-F. Structural and functional properties of human multidrug sresistance protein 1 (MRP1/ABCC1). Curr Med Chem. 2011;18(3):439-481.
Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene. 2003;22(47):7340-7358.
Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2(1):48-58.
Lemos C, Jansen G, Peters G. Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors. Br J Cancer. 2008;98(5):857-862.
Wolfe SA, Nekludova L, Pabo CO. DNA recognition by Cys2His2 zinc finger proteins. Annu Rev Biophys Biomol Struct. 2000;29(1):183-212.
Eom KS, Cheong JS, Lee SJ. Structural analyses of zinc finger domains for specific interactions with DNA. J Microbiol Biotechnol. 2016;26(12):2019-2029.
Krishna SS, Majumdar I, Grishin NV. Structural classification of zinc fingers: survey and summary. Nucleic Acids Res. 2003;31(2):532-550.
Cassandri M, Smirnov A, Novelli F, et al. Zinc-finger proteins in health and disease. Cell Death Discov. 2017;3:17071.
Tao C, Luo J, Tang J, et al. The tumor suppressor zinc finger protein 471 suppresses breast cancer growth and metastasis through inhibiting AKT and Wnt/β-catenin signaling. Clin Epigenetics. 2020;12(1):1-14.
Xie G, Peng Z, Liang J, et al. Zinc finger protein 277 is an intestinal transit-amplifying cell marker and colon cancer oncogene. JCI Insight. 2022;7(4):e150894.
Zhang J, Cheng Q, Zhou Y, Wang Y, Chen X. Slug is a key mediator of hypoxia induced cadherin switch in HNSCC: correlations with poor prognosis. Oral Oncol. 2013;49(11):1043-1050.
Chen C-Y, Yang S-C, Lee K-H, et al. The antitumor agent PBT-1 directly targets HSP90 and hnRNP A2/B1 and inhibits lung adenocarcinoma growth and metastasis. J Med Chem. 2014;57(3):677-685.
Saad S, Stanners S, Yong R, Tang O, Pollock C. Notch mediated epithelial to mesenchymal transformation is associated with increased expression of the snail transcription factor. Int J Biochem Cell Biol Cell B. 2010;42(7):1115-1122.
Zhang K, Zhaos J, Liu X, et al. Activation of NF-B upregulates snail and consequent repression of E-cadherin in cholangiocarcinoma cell invasion. Hepatogastroenterology. 2011;58(105):1-7.
Chen Y, Niu J, Li L, et al. Polydatin executes anticancer effects against glioblastoma multiforme by inhibiting the EGFR-AKT/ERK1/2/STAT3-SOX2/snail signaling pathway. Life Sci. 2020;258:118158.
Li T, Kong A-NT, Ma Z, et al. Protein arginine methyltransferase 1 may be involved in pregnane x receptor-activated overexpression of multidrug resistance 1 gene during acquired multidrug resistant. Oncotarget. 2016;7(15):20236-20248.
Nieto MA. The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol. 2002;3(3):155-166.
Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871-890.
Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 2007;7(6):415-428.
Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29(34):4741-4751.
Mladinich M, Ruan D, Chan C-H. Tackling cancer stem cells via inhibition of EMT transcription factors. Int J Stem Cells. 2016;2016:1-10.
Deng J-J, Zhang W, Xu X-M, et al. Twist mediates an aggressive phenotype in human colorectal cancer cells. Int J Oncol. 2016;48(3):1117-1124.
Roberts CM, Shahin SA, Wen W, et al. Nanoparticle delivery of siRNA against TWIST to reduce drug resistance and tumor growth in ovarian cancer models. Nanomedicine. 2017;13(3):965-976.
Wang N, Guo D, Zhao Y, et al. TWIST-1 promotes cell growth, drug resistance and progenitor clonogenic capacities in myeloid leukemia and is a novel poor prognostic factor in acute myeloid leukemia. Oncotarget. 2015;6(25):20977-20992.
Li R, Wu C, Liang H, et al. Knockdown of TWIST enhances the cytotoxicity of chemotherapeutic drugs in doxorubicin-resistant HepG2 cells by suppressing MDR1 and EMT. Int J Oncol. 2018;53(4):1763-1773.
Sánchez-Tilló E, de Barrios O, Siles L, Cuatrecasas M, Castells A, Postigo A. β-Catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness. Proc Natl Acad Sci U S A. 2011;108(48):19204-19209.
Liu C, He S, Zhang J, Li S, Chen J, Han C. Silencing TCF4 sensitizes melanoma cells to vemurafenib through inhibiting GLUT3-mediated glycolysis. Onco Targets Ther. 2020;13:4905-4915.
Paranjape A, Soundararajan R, Werden S, et al. Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties. Oncogene. 2016;35(46):5963-5976.
Wang Y, Shi J, Chai K, Ying X, Zhou BP. The role of snail in EMT and tumorigenesis. Curr Cancer Drug Targets. 2013;13(9):963-972.
Kast RE, Skuli N, Karpel-Massler G, Frosina G, Ryken T, Halatsch M-E. Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen. Oncotarget. 2017;8(37):60727-60749.
Santamaria PG, Moreno-Bueno G, Portillo F, Cano A. EMT: present and future in clinical oncology. Mol Oncol. 2017;11(7):718-738.
Nantajit D, Lin D, Li JJ. The network of epithelial-mesenchymal transition: potential new targets for tumor resistance. J Cancer Res Clin. 2015;141(10):1697-1713.
van Staalduinen J, Baker D, ten Dijke P, van Dam H. Epithelial-mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer? Oncogene. 2018;37(48):6195-6211.
Huang W, Chen J, Liu X, et al. MIER3 induces epithelial-mesenchymal transition and promotes breast cancer cell aggressiveness via forming a co-repressor complex with HDAC1/HDAC2/snail. Exp Cell Res. 2021;406(1):112722.
Cai F, Xiao H, Sun Y, Wang D, Tang J. Expression of snail and E-cadherin in drug-resistant MCF-7/ADM breast cancer cell strains. J Coll Physicians Surg Pak. 2019;29:240-244.
Prokop JW, Liu Y, Milsted A, Peng H, Rauscher FJ. A method for in silico identification of SNAIL/SLUG DNA binding potentials to the E-box sequence using molecular dynamics and evolutionary conserved amino acids. J Mol Model. 2013;19(9):3463-3469.
Bottner J, Ribbat-Idel J, Klapper L, et al. Elevated LSD1 and SNAIL expression indicate poor prognosis in hypopharynx carcinoma. Int J Mol Sci. 2022;23(9):5075.
Liu W-S, Chan S-H, Chang H-T, et al. Isocitrate dehydrogenase 1-snail axis dysfunction significantly correlates with breast cancer prognosis and regulates cell invasion ability. Breast Cancer Res. 2018;20(1):1-17.
Zhang W, Feng M, Zheng G, et al. Chemoresistance to 5-fluorouracil induces epithelial-mesenchymal transition via up-regulation of snail in MCF7 human breast cancer cells. Biochem Biophys Res. 2012;417(2):679-685.
Haslehurst AM, Koti M, Dharsee M, et al. EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer. 2012;12(1):91.
Mezencev R, Matyunina LV, Jabbari N, McDonald JF. Snail-induced epithelial-to-mesenchymal transition of MCF-7 breast cancer cells: systems analysis of molecular changes and their effect on radiation and drug sensitivity. BMC Cancer. 2016;16(1):236.
Dong J, Zhai B, Sun W, Hu F, Cheng H, Xu J. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells. PloS One. 2017;12(9):e0185088.
Grotegut S, von Schweinitz D, Christofori G, Lehembre F. Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-mediated upregulation of snail. EMBO J. 2006;25(15):3534-3545.
Lu M, Xiao L, Hu J, Deng S, Xu Y. Targeting of p38 mitogen-activated protein kinases to early growth response gene 1 (EGR-1) in the human paclitaxel-resistance ovarian carcinoma cells. J Huazhong U Sci Med. 2008;28(4):451-455.
Tokura Y, Shikami M, Miwa H, et al. Augmented expression of P-gp/multi-drug resistance gene by all-trans retinoic acid in monocytic leukemic cells. Leuk Res. 2002;26(1):29-36.
Chen J-S, Li H-S, Huang J-Q, et al. Down-regulation of Gli-1 inhibits hepatocellular carcinoma cell migration and invasion. Mol Cell Biochem. 2014;393(1-2):283-291.
Saxena M, Stephens MA, Pathak H, Rangarajan A. Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis. 2011;2(7):e179.
Wang H, Li JM, Wei W, et al. Regulation of ATP-binding cassette subfamily B member 1 by snail contributes to chemoresistance in colorectal cancer. Cancer Sci. 2020;111(1):84-97.
Kaşıkcı E, Aydemir E, Bayrak ÖF, Şahin F. Inhibition of migration, invasion and drug resistance of pancreatic adenocarcinoma cells-role of snail, slug and Twist and small molecule inhibitors. Onco Targets Ther. 2020;13:5763-5777.
Li S, Fan Y, Kumagai A, et al. Deficiency in dipeptidyl peptidase-4 promotes chemoresistance through the CXCL12/CXCR4/mTOR/TGFβ signaling pathway in breast cancer cells. Int J Mol Sci. 2020;21(3):805.
Xie M, He C-S, Wei S-H, Zhang L. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo. Eur J Cancer. 2013;49(16):3559-3572.
Namba T, Kodama R, Moritomo S, Hoshino T, Mizushima T. Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3 β-snail pathway. Cell Death Dis. 2015;6(6):e1795-e.
Tomono T, Yano K, Ogihara T. Snail-induced epithelial-to-mesenchymal transition enhances P-gp-mediated multidrug resistance in HCC827 cells. J Pharm Sci. 2017;106(9):2642-2649.
Escriva M, Peiró S, Herranz N, et al. Repression of PTEN phosphatase by Snail1 transcriptional factor during gamma radiation-induced apoptosis. Mol and Cel Biol. 2008;28(5):1528-1540.
Kaufhold S, Bonavida B. Central role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic intervention. J Exp Clin Canc Res. 2014;33(1):62.
Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets. 2008;8(3):187-198.
De Herreros AG, Peiró S, Nassour M, Savagner P. Snail family regulation and epithelial mesenchymal transitions in breast cancer progression. J Mammary Gland Biol Neoplasia. 2010;15(2):135-147.
Liu W-H, Chen M-T, Wang M-L, et al. Cisplatin-selected resistance is associated with increased motility and stem-like properties via activation of STAT3/snail axis in atypical teratoid/rhabdoid tumor cells. Oncotarget. 2015;6(3):1750-1768.
Wadhwa B, Paddar M, Khan S, et al. AKT isoforms have discrete expression in triple negative breast cancers and roles in cisplatin sensitivity. Oncotarget. 2020;11(45):4178-4194.
Dohadwala M, Yang S-C, Luo J, et al. Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E2 induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. Cancer Res. 2006;66(10):5338-5345.
li Ma J, Zeng S, Zhang Y, lu Deng G, Shen H. Epithelial-mesenchymal transition plays a critical role in drug resistance of hepatocellular carcinoma cells to oxaliplatin. Tumor Biol. 2016;37(5):6177-6184.
Imai T, Horiuchi A, Wang C, et al. Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am J Pathol. 2003;163(4):1437-1447.
Mishra AB, Nishank SS. Therapeutic targeting approach on epithelial-mesenchymal plasticity to combat cancer metastasis. Med Oncol. 2023;40(7):190.
Tam SY, Wu VW, Law HK. Hypoxia-induced epithelial-mesenchymal transition in cancers: HIF-1α and beyond. Front Oncol. 2020;10:486.
Baram T, Rubinstein-Achiasaf L, Ben-Yaakov H, Ben-Baruch A. Inflammation-driven breast tumor cell plasticity: Stemness/EMT, therapy resistance and dormancy. Front Oncol. 2021;10:614468.
Wu Y-d, Zhou B. TNF-α/NF-κB/snail pathway in cancer cell migration and invasion. Br J Cancer. 2010;102(4):639-644.
Brozovic A. The relationship between platinum drug resistance and epithelial-mesenchymal transition. Arch Toxicol. 2017;91(2):605-619.
Yang N, Zhang H, Cai X, Shang Y. Epigallocatechin-3-gallate inhibits inflammation and epithelial-mesenchymal transition through the PI3K/AKT pathway via upregulation of PTEN in asthma. Int J Mol Med. 2018;41(2):818-828.
Leng Z, Li Y, Zhou G, et al. Krüppel-like factor 4 regulates stemness and mesenchymal properties of colorectal cancer stem cells through the TGF-β1/Smad/snail pathway. J Cell Mol Med. 2020;24(2):1866-1877.
Stewart TA, Azimi I, Thompson EW, Roberts-Thomson SJ, Monteith GR. A role for calcium in the regulation of ATP-binding cassette, sub-family C, member 3 (ABCC3) gene expression in a model of epidermal growth factor-mediated breast cancer epithelial-mesenchymal transition. Biochem Biophys Res Commun. 2015;458(3):509-514.
Yin L, Castagnino P, Assoian RK. ABCG2 expression and side population abundance regulated by a transforming growth factor β-directed epithelial-mesenchymal transition. Cancer Res. 2008;68(3):800-807.
Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976;455(1):152-162.
da Costa KM, Freire-de-Lima L, da Fonseca LM, Previato JO, Mendonça-Previato L, Valente RC. ABCB1 and ABCC1 function during TGF-β-induced epithelial-mesenchymal transition: relationship between multidrug resistance and tumor progression. Int J Mol Sci. 2023;24(7):6046.
Jiang Z-S, Sun Y-Z, Wang S-M, Ruan J-S. Epithelial-mesenchymal transition: potential regulator of ABC transporters in tumor progression. J Cancer. 2017;8(12):2319-2327.
Yang Y, Zhang N, Zhu J, et al. Downregulated connexin32 promotes EMT through the Wnt/β-catenin pathway by targeting snail expression in hepatocellular carcinoma. Int J Oncol. 2017;50(6):1977-1988.
Ma X, Wang J, Zhuang J, et al. P4HB modulates epithelial-mesenchymal transition and the β-catenin/snail pathway influencing chemoresistance in liver cancer cells. Oncol Lett. 2020;20(1):257-265.
Kotoh M, Katoh M. Cross-talk of WNT and FGF signaling pathways at GSK3β to regulate β-catenin and SNAIL signaling cascades. Cancer Biol Ther. 2006;5(9):1059-1064.
Stemmer V, De Craene B, Berx G, Behrens J. Snail promotes Wnt target gene expression and interacts with β-catenin. Oncogene. 2008;27(37):5075-5080.
Zhang L, Wu J, Feng Y, et al. A regulatory loop involving notch and Wnt signaling maintains leukemia stem cells in T-cell acute lymphoblastic leukemia. Front Cell Dev Biol. 2021;9:678544.
BeLow M, Osipo C. Notch signaling in breast cancer: a role in drug resistance. Cell. 2020;9(10):2204.
Rani A, Greenlaw R, Smith RA, Galustian C. HES1 in immunity and cancer. Cytokine Growth Factor Rev. 2016;30:113-117.
Sun L, Ke J, He Z, et al. HES1 promotes colorectal cancer cell resistance to 5-Fu by inducing of EMT and ABC transporter proteins. J Cancer. 2017;8(14):2802-2808.
Lee SH, Do SI, Lee HJ, Kang HJ, Koo BS, Lim YC. Notch1 signaling contributes to stemness in head and neck squamous cell carcinoma. Lab Invest. 2016;96(5):508-516.
Danielpour D, Corum S, Leahy P, Bangalore A. Jagged-1 is induced by mTOR inhibitors in renal cancer cells through an Akt/ALK5/Smad4-dependent mechanism. Curr Res Pharmacol Drug Discov. 2022;3:100117.
Yang X, Shang P, Yu B, et al. Combination therapy with miR34a and doxorubicin synergistically inhibits dox-resistant breast cancer progression via down-regulation of snail through suppressing notch/NF-κB and RAS/RAF/MEK/ERK signaling pathway. Acta Pharm Sin B. 2021;11(9):2819-2834.
Shirley SH, Hudson LG, He J, Kusewitt DF. The skinny on slug. Mol Carcinogen. 2010;49(10):851-861.
Yang HW, Menon LG, Black PM, Carroll RS, Johnson MD. SNAI2/slug promotes growth and invasion in human gliomas. BMC Cancer. 2010;10(1):301.
Kim J, Shin K, Lee SH, Kim I-H. Slug and CD133 expression are associated with peritoneal carcinomatosis and survival in gastric cancer. J Gastrointest Oncol. 2021;12(4):1326-1337.
Qiu W-L, Tseng A-J, Hsu H-Y, et al. Fucoidan increased the sensitivity to gefitinib in lung cancer cells correlates with reduction of TGFβ-mediated slug expression. Int J Biol Macromol. 2020;153:796-805.
Karaosmanoğlu O, Banerjee S, Sivas H. Identification of biomarkers associated with partial epithelial to mesenchymal transition in the secretome of slug over-expressing hepatocellular carcinoma cells. Cell Oncol. 2018;41(4):439-453.
Tsou S-H, Chen T-M, Hsiao H-T, Chen Y-H. A critical dose of doxorubicin is required to alter the gene expression profiles in MCF-7 cells acquiring multidrug resistance. PLoS One. 2015;10(1):e0116747.
Uygur B, Abramo K, Leikina E, Vary C, Liaw L, Wu WS. SLUG is a direct transcriptional repressor of PTEN tumor suppressor. Prostate. 2015;75(9):907-916.
Van Grunsven LA, Taelman V, Michiels C, Opdecamp K, Huylebroeck D, Bellefroid EJ. δEF1 and SIP1 are differentially expressed and have overlapping activities during Xenopus embryogenesis. Dev Dyn. 2006;235(6):1491-1500.
Zhang X, Zhang Z, Zhang Q, et al. ZEB1 confers chemotherapeutic resistance to breast cancer by activating ATM. Cell Death Dis. 2018;9(2):57.
Siebzehnrubl FA, Silver DJ, Tugertimur B, et al. The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance. EMBO. 2013;5(8):1196-1212.
Zhang P, Liu H, Xia F, et al. Epithelial-mesenchymal transition is necessary for acquired resistance to cisplatin and increases the metastatic potential of nasopharyngeal carcinoma cells. Int J Mol Med. 2014;33(1):151-159.
Iderzorig T, Kellen J, Osude C, et al. Comparison of EMT mediated tyrosine kinase inhibitor resistance in NSCLC. Biochem Biophys Res. 2018;496(2):770-777.
Ren J, Chen Y, Song H, Chen L, Wang R. Inhibition of ZEB1 reverses EMT and chemoresistance in docetaxel-resistant human lung adenocarcinoma cell line. J Cell Biochem. 2013;114(6):1395-1403.
Hara J, Miyata H, Yamasaki M, et al. Mesenchymal phenotype after chemotherapy is associated with chemoresistance and poor clinical outcome in esophageal cancer. Oncol Rep. 2014;31(2):589-596.
Mato E, Gonzalez C, Moral A, et al. ABCG2/BCRP gene expression is related to epithelial-mesenchymal transition inducer genes in a papillary thyroid carcinoma cell line (TPC-1). J Mol Endocrinol. 2014;52(3):289-300.
Meidhof S, Brabletz S, Lehmann W, et al. ZEB 1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat. EMBO Mol Med. 2015;7(6):831-847.
Comijn J, Berx G, Vermassen P, et al. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell. 2001;7(6):1267-1278.
Frigo DE, Bondesson M, Williams C. Nuclear receptors: from molecular mechanisms to therapeutics. Essays Biochem. 2021;65(6):847-856.
Wan L-Y, Zhang Y-Q, Chen M-D, Liu C-B, Wu J-F. Relationship of structure and function of DNA-binding domain in vitamin D receptor. Molecules. 2015;20(7):12389-12399.
Carnahan VE, Redinbo MR. Structure and function of the human nuclear xenobiotic receptor PXR. Curr Drug Metab. 2005;6(4):357-367.
Zhuo W, Hu L, Lv J, Wang H, Zhou H, Fan L. Role of pregnane X receptor in chemotherapeutic treatment. Cancer Chemoth Pharm. 2014;74(2):217-227.
Xu HB, Tang ZQ, Wang J, Kong PS. Z-guggulsterone regulates MDR1 expression mainly through the pregnane X receptor-dependent manner in human brain microvessel endothelial cells. Eur J Pharmacol. 2020;874:173023.
Qiao E, Ji M, Wu J, et al. Expression of the PXR gene in various types of cancer and drug resistance. Oncol Lett. 2013;5(4):1093-1100.
Chen Y, Tang Y, Wang M-T, Zeng S, Nie D. Human pregnane X receptor and resistance to chemotherapy in prostate cancer. Cancer Res. 2007;67(21):10361-10367.
Albermann N, Schmitz-Winnenthal FH, Z'graggen K, et al. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol. 2005;70(6):949-958.
Matheux A, Gassiot M, Fromont G, et al. PXR modulates the prostate cancer cell response to afatinib by regulating the expression of the monocarboxylate transporter SLC16A1. Cancer. 2021;13(14):3635.
Chen Y, Tang Y, Chen S, Nie D. Regulation of drug resistance by human pregnane X receptor in breast cancer. Cancer Biol Ther. 2009;8(13):1265-1272.
Whyte-Allman S-K, Hoque MT, Jenabian M-A, Routy J-P, Bendayan R. Xenobiotic nuclear receptors Pregnane X receptor and constitutive androstane receptor regulate antiretroviral drug efflux transporters at the blood-testis barrier. J Pharmacol Exp Ther. 2017;363(3):324-335.
Chen T. Overcoming drug resistance by regulating nuclear receptors. Adv Drug Deliv Rev. 2010;62(13):1257-1264.
Sandanaraj E, Lal S, Selvarajan V, et al. PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients. Clin Cancer Res. 2008;14(21):7116-7126.
Yang H, Ren L, Wang Y, et al. FBI-1 enhanced the resistance of triple-negative breast cancer cells to chemotherapeutic agents via the miR-30c/PXR axis. Cell Death Dis. 2020;11(10):1-14.
Larriba MJ, Munoz A. SNAIL vs vitamin D receptor expression in colon cancer: therapeutics implications. Br J Cancer. 2005;92(6):985-989.
Crew KD, Shane E, Cremers S, McMahon DJ, Irani D, Hershman DL. High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. J Clin Oncol. 2009;27(13):2151-2156.
Shahvegharasl Z, Pirouzpanah S, Mahboob SA, et al. Effects of cholecalciferol supplementation on serum angiogenic biomarkers in breast cancer patients treated with tamoxifen: a controlled randomized clinical trial. Nutrition. 2020;72:110656.
Tachibana S, Yoshinari K, Chikada T, Toriyabe T, Nagata K, Yamazoe Y. Involvement of vitamin D receptor in the intestinal induction of human ABCB1. Drug Metab Dispos. 2009;37(8):1604-1610.
Noh K, Chow EC, Quach HP, Groothuis GM, Tirona RG, Pang KS. Significance of the vitamin D receptor on crosstalk with nuclear receptors and regulation of enzymes and transporters. AAPS J. 2022;24(4):71.
Kota BP, Allen JD, Roufogalis BD. The effect of vitamin D3 and ketoconazole combination on VDR-mediated P-gp expression and function in human colon adenocarcinoma cells: implications in drug disposition and resistance. Basic Clin Pharmacol Toxicol. 2011;109(2):97-102.
Chow EC, Durk MR, Cummins CL, Pang KS. 1α, 25-Dihydroxyvitamin D3 up-regulates P-glycoprotein via the vitamin D receptor and not farnesoid X receptor in both fxr (−/−) and fxr (+/+) mice and increased renal and brain efflux of digoxin in mice in vivo. J Pharmacol Exp Ther. 2011;337(3):846-859.
Saeki M, Kurose K, Tohkin M, Hasegawa R. Identification of the functional vitamin D response elements in the human MDR1 gene. Biochem Pharmacol. 2008;76(4):531-542.
Heymann W. Metabolism and mode of action of vitamin D. 2. Storage of vitamin D in different tissues in vivo. J Biol Chem. 1937;118:371-376.
Pirouzpanah S, Taleban FA, Atri M, Abadi AR, Mehdipour P. The effect of modifiable potentials on hypermethylation status of retinoic acid receptor-beta2 and estrogen receptor-alpha genes in primary breast cancer. Cancer Causes Control. 2010;21(12):2101-2111.
Mehdipour P, Pirouzpanah S, Sarafnejad A, Atri M, Shahrestani ST, Haidari M. Prognostic implication of CDC25A and cyclin E expression on primary breast cancer patients. Cell Biol Int. 2009;33(10):1050-1056.
Pirouzpanah S, Taleban FA, Mehdipour P, Atri M, Foroutan-Ghaznavi M. Plasma total homocysteine level in association with folate, pyridoxine, and cobalamin status among Iranian primary breast cancer patients. Nutr Cancer. 2014;66(7):1097-1108.
Pirouzpanah S, Taleban FA, Mehdipour P, Sabour S, Atri M. Hypermethylation pattern of ESR and PgR genes and lacking estrogen and progesterone receptors in human breast cancer tumors: ER/PR subtypes. Cancer Biomark. 2018;21(3):621-638.
Mehdipour P, Pirouzpanah S, Kheirollahi M, Atri M. Androgen receptor gene CAG repeat polymorphism and breast cancer risk in Iranian women: a case-control study. Breast J. 2011;17(1):39-46.
Bai Z, Gust R. Breast cancer, estrogen receptor and ligands. Arch Pharm. 2009;342(3):133-149.
Beyersmann D, Hartwig A. Carcinogenic metal compounds: recent insight into molecular and cellular mechanisms. Arch Toxicol. 2008;82(8):493-512.
Zeng L, Zielinska H, Arshad A, et al. Hyperglycaemia-induced chemoresistance in breast cancer cells: role of the estrogen receptor. Endocr Relat Cancer. 2016;23(2):125-134.
Liu L, Zhao T, Shan L, Cao L, Zhu X, Xue Y. Estradiol regulates intestinal ABCG2 to promote urate excretion via the PI3K/Akt pathway. Nutr Metab (Lond). 2021;18(1):1-11.
Nedeljković M, Tanić N, Prvanović M, Milovanović Z, Tanić N. Friend or foe: ABCG2, ABCC1 and ABCB1 expression in triple-negative breast cancer. Breast Cancer. 2021;28(3):727-736.
Hartz AM, Mahringer A, Miller DS, Bauer B. 17-β-estradiol: a powerful modulator of blood-brain barrier BCRP activity. J Cereb Blood Flow Metab. 2010;30(10):1742-1755.
Mutoh K, Tsukahara S, Mitsuhashi J, Katayama K, Sugimoto Y. Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells. Cancer Sci. 2006;97(11):1198-1204.
Srivastava RAK. Estrogen-induced regulation of the ATP-binding cassette transporter A1 (ABCA1) in mice: a possible mechanism of atheroprotection by estrogen. Mol Cell Biochem. 2002;240(1-2):67-73.
Ee PLR, Kamalakaran S, Tonetti D, He X, Ross DD, Beck WT. Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene. Cancer Res. 2004;64(4):1247-1251.
Yu T, Cheng H, Ding Z, et al. GPER mediates decreased chemosensitivity via regulation of ABCG2 expression and localization in tamoxifen-resistant breast cancer cells. Mol Cell Endocrinol. 2020;506:110762.
Diao Y, Azatyan A, Rahman MF-U, et al. Blockade of the hedgehog pathway downregulates estrogen receptor alpha signaling in breast cancer cells. Oncotarget. 2016;7(44):71580-71593.
Guo S, Li Y, Tong Q, et al. δEF1 down-regulates ER-α expression and confers tamoxifen resistance in breast cancer. PloS One. 2012;7(12):e52380.
Li T-t, Liu M-r, Pei D-s. Friend or foe, the role of EGR-1 in cancer. Med Oncol. 2020;37(1):7.
Pirouzpanah S, Taleban FA, Mehdipour P, Atri M. Association of folate and other one-carbon related nutrients with hypermethylation status and expression of RARB, BRCA1, and RASSF1A genes in breast cancer patients. J Mol Med. 2015;93(8):917-934.
Beishline K, Azizkhan-Clifford J. Sp1 and the ‘hallmarks of cancer’. FEBS J. 2015;282(2):224-258.
Li L, Davie JR. The role of Sp1 and Sp3 in normal and cancer cell biology. Ann Anat. 2010;192(5):275-283.
Zeng J, Heuchel R, Schaffner W, Kägi JH. Thionein (apometallothionein) can modulate DNA binding and transcription activation by zinc finger containing factor Spl. FEBS Lett. 1991;279(2):310-312.
Larabee JL, Hocker JR, Hanas JS. Mechanisms of inhibition of zinc-finger transcription factors by selenium compounds ebselen and selenite. J Inorg Biochem. 2009;103(3):419-426.
Thiesen H-J, Bach C. Transition metals modulate DNA-protein interactions of SP1 zinc finger domains with its cognate target site. Biochem Biophys Res. 1991;176(2):551-557.
Borellini F, Aquino A, Josephs S, Glazer R. Increased expression and DNA-binding activity of transcription factor Sp1 in doxorubicin-resistant HL-60 leukemia cells. Mol Cell Biol. 1990;10(10):5541-5547.
Zhang Q, Yan G, Lei J, et al. The SP1-12LOX axis promotes chemoresistance and metastasis of ovarian cancer. Mol Med. 2020;26(1):1-9.
Yang W-J, Song M-J, Park EY, et al. Transcription factors Sp1 and Sp3 regulate expression of human ABCG2 gene and chemoresistance phenotype. Mol Cells. 2013;36(4):368-375.
Li J, Wu X, Gong J, et al. Vascular endothelial growth factor induces multidrug resistance-associated protein 1 overexpression through phosphatidylinositol-3-kinase/protein kinase B signaling pathway and transcription factor specificity protein 1 in BGC823 cell line. Acta Biochim Biophys Sin. 2013;45(8):656-663.
Woo SK, Kwon MS, Geng Z, et al. Sequential activation of hypoxia-inducible factor 1 and specificity protein 1 is required for hypoxia-induced transcriptional stimulation of Abcc8. J Cereb Blood Flow Metab. 2012;32(3):525-536.
Davis W Jr, Chen ZJ, Ile KE, Tew KD. Reciprocal regulation of expression of the human adenosine 5′-triphosphate binding cassette, sub-family a, transporter 2 (ABCA2) promoter by the early growth response-1 (EGR-1) and Sp-family transcription factors. Nucleic Acids Res. 2003;31(3):1097-1107.
McCoy C, Smith DE, Cornwell MM. 12-O-tetradecanoylphorbol-13-acetate activation of the MDR1 promoter is mediated by EGR1. Mol Cell Biol. 1995;15(11):6100-6108.
Nishida Y, Mizutani N, Inoue M, et al. Phosphorylated Sp1 is the regulator of DNA-PKcs and DNA ligase IV transcription of daunorubicin-resistant leukemia cell lines. Biochim Biophys Acta. 2014;1839(4):265-274.
Douet V, Heller MB, Le Saux O. DNA methylation and Sp1 binding determine the tissue-specific transcriptional activity of the mouse Abcc6 promoter. Biochem Biophys Res. 2007;354(1):66-71.
Doush Y, Surani AA, Navarro-Corcuera A, McArdle S, Billett EE, Montiel-Duarte C. SP1 and RARα regulate AGAP2 expression in cancer. Sci Rep. 2019;9(1):1-12.
Wang W, Yang C, Wang XY, et al. MicroRNA-129 and-335 promote diabetic wound healing by inhibiting Sp1-mediated MMP-9 expression. Diabetes. 2018;67(8):1627-1638.
Feldman D, Leahy E, Lee S-H. Chemopreventive properties of tolfenamic acid: a mechanistic review. Curr Med Chem. 2018;25(14):1598-1608.
Upadhyaya B, Liu Y, Dey M. Phenethyl isothiocyanate exposure promotes oxidative stress and suppresses Sp1 transcription factor in cancer stem cells. Int J Mol Sci. 2019;20(5):1027.
McConnell BB, Yang VW. Mammalian Krüppel-like factors in health and diseases. Physiol Rev. 2010;90(4):1337-1381.
Limame R, de Beeck KO, Lardon F, De Wever O, Pauwels P. Krüppel-like factors in cancer progression: three fingers on the steering wheel. Oncotarget. 2014;5(1):29-48.
Meyer SE, Hasenstein JR, Baktula A, et al. Krüppel-like factor 5 is not required for K-RasG12D lung tumorigenesis, but represses ABCG2 expression and is associated with better disease-specific survival. Am J Pathol. 2010;177(3):1503-1513.
Yu G, Wu F, Wang E. KLF8 promotes temozolomide resistance in glioma cells via β-catenin activation. Cell Physiol Biochem. 2016;38(4):1596-1604.
Zhang H, Sun L, Xiao X, et al. Krüppel-like factor 8 contributes to hypoxia-induced MDR in gastric cancer cells. Cancer Sci. 2014;105(9):1109-1115.
Ho EA, Piquette-Miller M. KLF6 and HSF4 transcriptionally regulate multidrug resistance transporters during inflammation. Biochem Biophys Res. 2007;353(3):679-685.
Duz MB, Karatas OF. Differential expression of ABCB1, ABCG2, and KLF4 as putative indicators for paclitaxel resistance in human epithelial type 2 cells. Mol Biol Rep. 2021;48(2):1393-1400.
An Z-j, Li Y, Tan B-b, et al. Up-regulation of KLF17 expression increases the sensitivity of gastric cancer to 5-fluorouracil. Int J Immunopathol Pharmacol. 2021;35:20587384211010925.
Wang Z, Qiu X, Zhang H, Li W. KLF5 influences cell biological function and chemotherapy sensitivity through the JNK signaling pathway in anaplastic thyroid carcinoma. J Biochem Mol Toxicol. 2020;34(5):e22469.
Martin V, Sanchez-Sanchez AM, Herrera F, et al. Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells. Br J Cancer. 2013;108(10):2005-2012.
Cui DM, Zeng T, Ren J, et al. KLF 4 knockdown attenuates TBI-induced neuronal damage through p53 and JAK-STAT 3 signaling. CNS Neurosci Ther. 2017;23(2):106-118.
Pujol-López M, Ortega-Paz L, Garabito M, Brugaletta S, Sabaté M, Dantas AP. miRNA update: a review focus on clinical implications of miRNA in vascular remodeling. AIMS Med Sci. 2017;4:99-112.
Han M, Wang Y, Guo G, et al. MicroRNA-30d mediated breast cancer invasion, migration, and EMT by targeting KLF11 and activating STAT3 pathway. J Cell Biochem. 2018;119(10):8138-8145.
Farrugia MK, Vanderbilt DB, Salkeni MA, Ruppert JM. Kruppel-like pluripotency factors as modulators of cancer cell therapeutic responses. Cancer Res. 2016;76(7):1677-1682.
Pandolfi S, Stecca B. Cooperative integration between hedgehog-GLI signalling and other oncogenic pathways: implications for cancer therapy. Expert Rev Mol Med. 2015;17:e5.
Yan S, Ma D, Ji M, et al. Expression profile of notch-related genes in multidrug resistant K562/A02 cells compared with parental K562 cells. Int J Lab Hematol. 2010;32(2):150-158.
Chen Z, Zhang L, Xia L, et al. Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling. Cancer Lett. 2014;350(1-2):43-51.
Sims-Mourtada J, Izzo J, Ajani J, Chao K. Sonic hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene. 2007;26(38):5674-5679.
Chen Y, Bieber MM, Teng NN. Hedgehog signaling regulates drug sensitivity by targeting ABC transporters ABCB1 and ABCG2 in epithelial ovarian cancer. Mol Carcinogen. 2014;53(8):625-634.
Zhang H, Hu L, Cheng M, Wang Q, Hu X, Chen Q. The hedgehog signaling pathway promotes chemotherapy resistance via multidrug resistance protein 1 in ovarian cancer. Oncol Rep. 2020;44(6):2610-2620.
Shahi M, Farheen S, Mariyath M, Castresana J. Potential role of Shh-Gli1-BMI1 signaling pathway nexus in glioma chemoresistance. Tumor Biol. 2016;37(11):15107-15114.
Das S, Samant RS, Shevde LA. Nonclassical activation of hedgehog signaling enhances multidrug resistance and makes cancer cells refractory to smoothened-targeting hedgehog inhibition. J Biol Chem. 2013;288(17):11824-11833.
Cui D, Xu Q, Wang K, Che X. Gli1 is a potential target for alleviating multidrug resistance of gliomas. J Neurol Sci. 2010;288(1-2):156-166.
Singh RR, Kunkalla K, Qu C, et al. ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. Oncogene. 2011;30(49):4874-4886.
Yu B, Gu D, Zhang X, Li J, Liu B, Xie J. GLI1-mediated regulation of side population is responsible for drug resistance in gastric cancer. Oncotarget. 2017;8(16):27412-27427.
Fantozzi A, Gruber DC, Pisarsky L, et al. VEGF-mediated angiogenesis links EMT-induced cancer stemness to tumor initiation. Cancer Res. 2014;74(5):1566-1575.
Cortes JE, Gutzmer R, Kieran MW, Solomon JA. Hedgehog signaling inhibitors in solid and hematological cancers. Cancer Treat Rev. 2019;76:41-50.
He J., Fortunati E., Liu D.-X., & Li Y.. Pleiotropic Roles of ABC Transporters in Breast Cancer. International Journal of Molecular Sciences. 2021;22(6):3199-3222.